(CGEN) Compugen Ltd. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CGEN) Compugen Ltd. Complete Analysis Pack
Download Your Competitive Advantage
This Compugen Ltd. 4P's Marketing Mix Analysis explains the company’s Product, Price, Place, and Promotion strategy and how it’s used for marketing research, benchmarking, and planning. The page shows a real preview/sample of the report so you can review style and content before buying—purchase the full version to unlock the complete ready-to-use analysis.
Product
COM701 anti-PVRIG antibody
COM701 is Compugen Ltd.’s lead immuno-oncology asset, an anti-PVRIG antibody in Phase I studies for solid tumors, so it sits in early development and not yet in commercialization. In a 4P view, its Product value is clinical differentiation, not sales scale. The key number is Phase I status, which means first-in-human testing and high clinical risk.
COM902 anti-TIGIT antibody
COM902 is Compugen Ltd.’s anti-TIGIT therapeutic antibody, in Phase I as a monotherapy for advanced malignancies. By moving beyond a single checkpoint target, it broadens the oncology pipeline and supports a more diversified product mix. TIGIT programs remain early-stage, so value hinges on clinical readouts and safety signals.
Bapotulimab ILDR2 antibody
Bapotulimab is Compugen Ltd.’s ILDR2 antibody, now in Phase I for solid tumors. It expands the company’s immune-checkpoint pipeline and gives Compugen one more early-stage shot at oncology differentiation. Phase I is the first human test stage, so near-term data will be key for its commercial path.
AZD2936 bispecific antibody
AZD2936 is a bispecific antibody from Compugen Ltd. that blocks TIGIT and PD-1 in one molecule, aiming to lift anti-tumor immune activity with one combined mechanism. It is in Phase I/II testing in advanced or metastatic non-small cell lung cancer, showing Compugen Ltd.'s push toward multi-target oncology biology.
- TIGIT + PD-1 in one molecule
- Phase I/II in advanced NSCLC
- Built for multi-target cancer control
Myeloid-target immuno-oncology programs
Compugen Ltd.’s myeloid-target immuno-oncology programs are earlier-stage assets built to expand its pipeline beyond the lead candidates. The company places clear emphasis on myeloid biology, aiming at tumor-driven immune suppression and long-term product depth. In the Product pillar, this is a portfolio strategy, not a near-term revenue driver.
- Earlier-stage pipeline depth
- Focus on myeloid targets
- Supports long-term growth
Compugen’s Value Lies in a Broad, Early-Stage Pipeline
Compugen Ltd.’s Product mix is still early-stage: COM701, COM902, Bapotulimab, and AZD2936 are all in Phase I or Phase I/II, so the value lies in pipeline breadth, not current sales. The clearest product signal is clinical depth across PVRIG, TIGIT, ILDR2, and dual-checkpoint biology.
| Asset | Stage | Product role |
|---|---|---|
| COM701 | Phase I | PVRIG lead |
| AZD2936 | Phase I/II | TIGIT + PD-1 |
What is included in the product
Detailed Word Document
A concise, company-specific 4P’s analysis of Compugen Ltd.’s Product, Price, Place, and Promotion strategies, grounded in real market positioning.
Editable Excel File
Distills Compugen Ltd.’s 4Ps into a quick, easy-to-scan snapshot for faster strategy review and team alignment.
Reference Sources
Lists primary, reputable sources that validate Compugen Ltd. assumptions, speeding due diligence and giving a clear, traceable reference trail for investors and reviewers.
Place
Holon headquarters, Israel
Compugen Ltd. is headquartered in Holon, Israel, and the site anchors corporate leadership and research operations. That base supports close oversight of the company’s biotech pipeline and keeps core decision-making in Israel. It also reinforces Compugen’s identity as an Israeli biotech company with global reach.
Operations in Israel
Israel remains Compugen Ltd.’s core operating base, where the company was founded in 1993 and has kept its Israeli center for discovery and development work. That local base supports its early-stage R&D model and keeps product research close to its scientific teams and partners.
United States presence
Compugen Ltd.’s United States presence gives it access to the world’s largest biotechnology market and to dense clinical, scientific, and commercial networks in hubs like Boston, San Diego, and the Bay Area.
This footprint also supports global partnering, since many pharma and biotech deal teams, investors, and trial sites are based in the United States.
That reach matters for business development and helps Compugen stay close to key customers and collaborators.
Europe reach
Compugen Ltd. operates in Europe through its clinical and partnering footprint, which matters for multinational programs that need patient access across more than one market. The EU has 27 member states, and adding UK/EEA sites can widen recruitment, localize evidence, and speed regulatory readiness for oncology trials.
- Broader patient access
- Stronger cross-border evidence
- Useful for multinational trials
Partner-led access channels
Compugen Ltd. uses partner-led access to push its science beyond its own sales footprint, and it names 3 major alliance partners: Bayer Pharma AG, Bristol-Myers Squibb, and AstraZeneca. This model gives Compugen wider reach into development and later commercialization without building a full commercial network alone. It also helps spread risk and keeps capital focused on R&D.
- 3 named global alliance partners
- Reach extends beyond in-house footprint
- Supports development and commercialization
Compugen’s Lean Global Reach from Holon to Biotech Hubs
Compugen Ltd.’s place strategy is centered in Holon, Israel, with R&D anchored in Israel and global reach through the United States and Europe. This base supports early discovery, partner access, and trial reach across major biotech hubs. Its model is lean: 3 named alliance partners extend reach without a large sales force.
| Place factor | Key data |
|---|---|
| HQ | Holon, Israel |
| Core base | Israel, founded 1993 |
| Alliance partners | 3 named |
| Major reach | US and Europe |
Get Your Copy
Compugen Ltd. Reference Sources
The preview shown here is the actual Compugen Ltd. 4P’s Marketing Mix document you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
Phase I and Phase I/II trial visibility
Compugen Ltd. promotes itself by spotlighting its Phase I and Phase I/II pipeline, a standard biotech way to build visibility through early human data. The message is simple: active studies signal scientific progress, even before revenue. For investors, each trial update becomes a marketing event tied to safety, dose, and proof-of-mechanism.
Strategic collaboration announcements
Compugen Ltd. uses collaboration announcements with Bayer, Bristol-Myers Squibb, Johns Hopkins, and AstraZeneca as third-party validation of its science. These ties lift visibility with investors and the oncology community, and they signal broader external trust. In 2025, the company listed 4 major partners in this promo set.
Scientific oncology positioning
Compugen Ltd. positions itself as a clinical-stage immuno-oncology company focused on immune checkpoint regulators and myeloid biology, so the message is precision cancer therapy, not broad oncology. In 2025, it was still pre-commercial, with no marketed oncology products, which fits a research-led promotion strategy. That keeps the brand tied to clinical validation and targeted mechanisms.
Data-driven corporate communication
Compugen Ltd’s promotion is built around clinical trial progress and research readouts, not consumer-style ads. The message focuses on safety, tolerability, and development updates, which fits a biotech company whose value depends on clinical proof.
- Clinical data first
- Safety and tolerability
- Evidence-based messaging
Global biotech credibility
Compugen uses its Israel, United States, and Europe footprint to signal global reach and execution depth. That multinational base helps build trust with partners and investors, especially for a Nasdaq-listed biotech company founded in 1993 and built for cross-border development. One message lands clearly: this is not a local story.
- Three-region footprint
- Stronger partner trust
- Investor credibility
- Built for global development
Compugen’s 2025 Edge: Clinical Data and Big-Name Validation
Compugen Ltd. promotes through clinical readouts, with 2025 messaging centered on safety, tolerability, and proof-of-mechanism in Phase I and Phase I/II oncology trials. Partnerships with Bayer, Bristol-Myers Squibb, Johns Hopkins, and AstraZeneca act as third-party validation. As a pre-commercial biotech, it leans on data, not ads.
| 2025 promo signal | Value |
|---|---|
| Major partners | 4 |
| Clinical stage | Phase I / I-II |
| Marketed products | 0 |
Price
No marketed product price
Compugen Ltd. is still a clinical-stage company, with investigational assets such as COM701 and COM902, so there is no public end-user price as of July 2026. Its revenue comes from collaboration and milestone payments, not commercial drug sales. So no marketed product price exists yet, and any pricing model will wait until approval.
Collaboration-based revenue model
Compugen Ltd. uses a collaboration-led price model: value comes from licensing, milestones, and royalties, not direct product sales. Its named partners include Bayer, Bristol-Myers Squibb, and AstraZeneca, so revenue is tied to deal terms and partner progress, not shelf pricing. That means the company monetizes pipeline assets through strategic alliances, with 3 major partners shaping cash flow.
Undisclosed deal economics
Compugen Ltd. has not disclosed the deal economics for these collaborations, so the price point cannot be verified from the public record. No upfront fee, milestone payment, or royalty rate is stated here. In this summary, pricing remains undisclosed.
Future oncology premium pricing potential
If Compugen Ltd.'s oncology assets win approval, pricing would likely track specialty oncology biologics, where annual U.S. list prices often exceed $100,000 per patient. Premium pricing is common because these drugs are complex to develop and serve small, biomarker-defined groups.
Actual net price would hinge on reimbursement, tender access, and payer rebates, so launch price and realized price can differ sharply.
Value tied to clinical success
Compugen Ltd.’s pricing power is tied to clinical readouts and partner progress. A positive Phase I or Phase I/II result can lift licensing value and improve deal terms, while a miss can cut future leverage fast. One strong data package can matter more than pipeline size.
- Positive data boosts licensing value
- Partner progress supports higher pricing
- Negative results weaken deal leverage
Compugen Has No Marketed Drug Price Yet
Compugen Ltd. has no marketed-product price as of July 2026 because it remains clinical-stage. Its monetization is deal-based, with revenue from collaboration and milestone payments rather than end-user sales, so any future price will depend on approval, reimbursement, and partner terms.
| Metric | 2026/2025 |
|---|---|
| Commercial drug price | None disclosed |
| Revenue model | Collaboration, milestones, royalties |
| Public deal economics | Not disclosed |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.